Entera Bio Correlations
| ENTX Stock | USD 1.72 0.02 1.15% |
The current 90-days correlation between Entera Bio and Anixa Biosciences is 0.19 (i.e., Average diversification). The correlation of Entera Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Entera Bio Correlation With Market
Significant diversification
The correlation between Entera Bio and DJI is 0.08 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Entera Bio and DJI in the same portfolio, assuming nothing else is changed.
Moving against Entera Stock
| 0.6 | DXB | Dimerix | PairCorr |
| 0.58 | DRTS | Alpha Tau Medical | PairCorr |
| 0.52 | VERA | Vera Therapeutics | PairCorr |
| 0.51 | 0P6S | Bayer AG NA | PairCorr |
| 0.47 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.37 | 688578 | Shanghai Allist Phar | PairCorr |
| 0.37 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.34 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.65 | SRZNW | Surrozen Warrant | PairCorr |
| 0.63 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.37 | VYNE | Vyne Therapeutics | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Entera Stock performing well and Entera Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Entera Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ANIX | 4.30 | 0.08 | 0.02 | 0.11 | 5.95 | 9.79 | 51.88 | |||
| VTGN | 5.40 | (1.03) | 0.00 | (0.83) | 0.00 | 7.93 | 96.59 | |||
| IRD | 3.30 | 0.32 | 0.08 | 0.34 | 3.80 | 7.45 | 26.50 | |||
| SEER | 1.51 | (0.36) | 0.00 | (0.33) | 0.00 | 3.17 | 9.98 | |||
| HURA | 4.61 | (1.62) | 0.00 | (0.43) | 0.00 | 7.73 | 50.34 | |||
| ABOS | 4.91 | 0.89 | 0.20 | 0.49 | 4.34 | 14.05 | 30.69 | |||
| MCRB | 4.39 | 0.10 | (0.01) | (0.02) | 6.25 | 10.42 | 54.10 | |||
| SPRO | 2.48 | 0.13 | 0.06 | 0.14 | 3.20 | 4.26 | 13.83 | |||
| AGEN | 2.72 | (0.52) | 0.00 | (0.17) | 0.00 | 4.34 | 21.03 | |||
| INO | 3.64 | (0.07) | 0.00 | (0.03) | 0.00 | 7.11 | 20.92 |
Entera Bio Corporate Management
| Hillel MBA | Chief Officer | Profile | |
| Miranda MBA | CEO Director | Profile | |
| II MD | Chief Officer | Profile | |
| Gregory Burshtein | Chief Development | Profile | |
| Dana CPA | Chief Officer | Profile | |
| Rachel Wagman | Chief Advisor | Profile | |
| RPh Itin | Head Bioanalytics | Profile |